EVALUATING THE EFFICACY OF TARGET PXT IN METASTATIC LIVER TUMORS
Mamatkulov Panji Khasanovich , Surkhandarya Branch Of Rio And Riatm, Uzbekistan Amanov Akmaljon Karimjonovich , Assistant, Termez Branch Of Tashkent Medical Academy, Uzbekistan Soatov Umidjon Abduganievich , Assistant, Termez Branch Of Tashkent Medical Academy, Uzbekistan Juraeva Gulbakhor Alisherovna , Assistant, Termez Branch Of Tashkent Medical Academy, UzbekistanAbstract
The goal of assessing tumour response on imaging is to identify patients who are likely to benefit — or not — from anticancer treatment, especially in relation to survival. The World Health Organization was the first to develop assessment criteria. This early score, which assessed tumour burden by standardising lesion size measurements, laid the groundwork for many of the criteria that followed. This was then improved by the Response Evaluation Criteria in Solid Tumours (RECIST) which was quickly adopted by the oncology community. At the same time, many interventional oncology treatments were developed to target specific features of liver tumours that result in significant changes in tumours but have little effect on tumour size. New criteria focusing on the viable part of tumours were therefore designed to provide more appropriate feedback to guide patient management. Targeted therapy has resulted in a breakthrough that challenges conventional response criteria due to the non-linear relationship between response and tumour size, requiring the development of methods that emphasize the appearance of tumours. More recently, research into functional and quantitative imaging has created new opportunities in liver imaging. These results have suggested that certain parameters could serve as early predictors of response or could predict later tumour response at baseline. These approaches have now been extended by machine learning and deep learning. This clinical review focuses on the progress made in the evaluation of liver tumours on imaging, discussing the rationale for this approach, addressing challenges and controversies in the field, and suggesting possible future developments.
Keywords
Liver, Imaging, Tumours
References
Organization W.H. World Health Organization; sold by WHO Publications Centre USA; Geneva and Albany, NY: 1979. WHO Handbook for Reporting Results of Cancer Treatment. [Google Scholar]
Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. [PubMed] [Google Scholar]
Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. [PubMed] [Google Scholar]
Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. [PubMed] [Google Scholar]
Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430. [
Article Statistics
Downloads
Metrics
Copyright License
Copyright (c) 2022 Mamatkulov Panji Khasanovich, Amanov Akmaljon Karimjonovich, Soatov Umidjon Abduganievich, Juraeva Gulbakhor Alisherovna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Individual articles are published Open Access under the Creative Commons Licence: CC-BY 4.0.